Introduction {#sec1-1}
============

Cardiovascular disease (CVD) is the major reason of mortality among noncommunicable diseases (NCDs), constituting 26% in India.\[[@ref1][@ref2]\] Relative to other NCDs, deprived quality of life and high mortality rate is mounting with CVDs regardless of highly developed health-care facilities. In India, patients with acute coronary syndrome (ACS) have higher rate of ST-elevation myocardial infarction (STEMI) than do patients in developed countries; the treatment options differ between rich and poor which significantly altered mortality and morbidity.\[[@ref3]\] Women develop CVD at older age and have greater comorbidities than men, though treatment and outcome did not differ after adjusting potential confounders.\[[@ref4]\] Appropriate and safe drug use is a key factor in achieving quality health and accurate health care for hospitalized as well as ambulatory patients. Extensive disparity exists in the pharmacotherapy pattern among CVD patients where rational drug use plays a pivotal role in promoting safety and efficacy. Polypharmacy is warranted in CVDs as it results in irrationality; hence, prescribing indicators were developed to assess the prescribing performance in primary care by the International Network for Rational Use of Drugs and World Health Organization (WHO).\[[@ref5]\]

Drug utilization research facilitates identification of clinical drug utilization and its impact on health-care system.\[[@ref6]\] Defined daily dose (DDD) is one such measurement which identifies the clinical drug use and it is defined as "the assumed average maintenance dose per day for a drug used for its main indication in adults."\[[@ref6]\] It is a unit of measurement and does not essentially correspond to the prescribed or recommended daily dose. Drug utilization studies in India demonstrate the occurrence of wide spectrum of various cardiovascular drugs utilized for prophylaxis and therapeutic indication.\[[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12]\] Continuous audit in critical care would provide insights into current practice and feedback for rationalizing prescribed practices.\[[@ref13]\] Hence, we proposed to study the drug utilization pattern by assessing the prescribing performance of teaching/referral hospital in Warangal, Telangana, India, using the WHO prescribing indicators and metric calculation DDD.

Materials and Methods {#sec1-2}
=====================

Study design and patients {#sec2-1}
-------------------------

A prospective observational study was conducted in a teaching/referral hospital in Warangal, Telangana, India, for a period of 7 months (January--July 2016), which included a total of 1120 patients admitted to intensive coronary care unit. The present study is a part of PhD thesis, where necessary permission from the hospital (No.: 350/UCPSc/KU/2015, Dated 10/12/2015) and ethics approval from Kakatiya Institutional Ethics Committee (KIEC) (Approval No.: KIEC/KMC/MGMH/NCT/2016/12/001b) were obtained for conduct of the study.

Methods {#sec2-2}
-------

All the medical prescriptions were collected and the data was used to analyze the prescription pattern by prescribing indicators\[[@ref13]\] and individual drug use by DDD measure. The WHO indicators intended to be used in primary care center/ambulatory patients, but in this study, it was extended to assess prescription pattern during hospitalization too. The prescribing indicators are (a) average number of drugs per prescription, (b) percentage of the drugs prescribed by their generic names, (c) percentage of the prescriptions with antibiotics prescribed, (d) percentage of the prescriptions with injections prescribed, and (e) percentage of the drugs prescribed from the essential drug list (EDL) or the hospital formulary.\[[@ref14]\]

The quantification of the individual drug was done using DDD. This concept was developed to surmount the objection besides the traditional measurement units of drug utilization. It is expressed as DDD (for each drug in individual patient); DDD/100 bed-days (for inpatients in a hospital); and DDD/1000 persons-years (for inhabitants in a region/country). In the present study, DDD was expressed as DDD/100 bed-days since inpatients\' drug use was considered and calculated using the equation below:\[[@ref6]\]
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Statistical analysis {#sec2-3}
--------------------

The data was collected, compiled in MS-Excel, and analyzed for counts and percentages. The mean and standard deviation was computed for continuous variables. Graphical representation has been used for visual interpretation of the analyzed data.

Results {#sec1-3}
=======

Sociodemographic characteristics {#sec2-4}
--------------------------------

Of the total 1120 records, males were 58.57% (55.19 ± 15.19 years) and females were 41.43% (56.64 ± 15.28 years). Majority of males were admitted between 61 and 70 years and females between 51 and 60 years of age. Surprisingly, the prevalence rate was high in males and mortality rate was high in females (9.7%). When screening inpatient prescriptions, it was found that 78.39% were discharged, 8.84% left against medical advice, 8.21% deaths, and 4.55% could not be tracked. Urbanization is predominant (57.05%) underlying determinant compared to rural life (42.95%) of the study population. The mean length of hospital stay was 5.889 ± 3.599 days. Deaths due to ischemic heart disease (IHD) would be the cause for developing arrhythmias and heart failure (HF). Coronary artery disease (55.27%) and cardiomyopathy (24.02%) were the common diagnoses, followed by hypertension and HF as depicted in [Figure 1](#F1){ref-type="fig"}.

![Prevalence of cardiovascular and noncardiovascular diseases in the study population in percentage](IJPharm-51-323-g002){#F1}

Drug utilization {#sec2-5}
----------------

A total of 12,941 drugs were prescribed during hospitalization and 5745 drugs at discharge. During hospitalization, 56.5% patients were given 7--12 drugs, 32.14% were given 13--18 drugs, and at discharge 50.63% were prescribed with 7--9 drugs. Number of drugs per prescription is depicted in [Figure 2](#F2){ref-type="fig"}.

![Number of drugs received per prescription in the study population](IJPharm-51-323-g003){#F2}

Drug utilization during hospitalization {#sec2-6}
---------------------------------------

The DDD of different cardiovascular drugs is summarized in [Table 1](#T1){ref-type="table"}; it was found that furosemide (109.33), atorvastatin (64.60), enalapril (58.43), aspirin (58.14), and clopidogrel (53.219) were highly used. Among various cardiovascular drugs, majority of prescriptions included antiplatelets, lipid-lowering agents, angiotensin-converting enzyme (ACE) inhibitors, diuretics, antianginals, anticoagulants, and beta blockers, as shown in [Table 2](#T2){ref-type="table"}.

###### 

Defined daily dose of cardiovascular drugs in the study population

  ATC code   Drug name                DDD/unit   ROA          Cases   DDD/100 bed-days
  ---------- ------------------------ ---------- ------------ ------- ------------------
  A02BC02    Pantoprazole             40 mg      O, P         903     63.91
  A10BA02    Metformin                2 g        O            255     2.27
  C01AA05    Digoxin                  0.25 mg    O, P         225     16.136
  C01BD01    Amiodarone               0.2 g      O, P         42      6.023
  C01CA03    Norepinephrine           6 mg       P            46      0.182
  C01CA07    Dopamine                 0.5 g      P            64      0.303
  C01CA08    Dobutamine               0.5 g      P            56      0.332
  C01DA08    Isosorbide dinitrate     20 mg      SL           515     38.472
  C01DA14    Isosorbide mononitrate   40 mg      O            59      2.193
  C01DA16    Nicorandil               40 mg      O            162     3.577
  C01DA17    Ivabradine               10 mg      O            11      0.771
  C03BA08    Metolazone               5 mg       O            169     27.742
  C03CA01    Furosemide               40 mg      O, P         715     109.33
  C03CA04    Torsemide                15 mg      O, P         18      1.03
  C03DA01    Spironolactone           75 mg      O            136     6.489
  C07AA05    Propranolol              0.16 g     O            1       0.025
  C07AB02    Metaprolol               0.15 g     O, P         467     11.737
  C07AB03    Atenolol                 75 mg      O, P         3       0.189
  C07AG01    Labetalol                0.6 g      O            8       0.006
  C07AG02    Carvedilol               37.5 mg    O            223     3.013
  C08CA01    Amlodipine               5 mg       P            69      5.371
  C08CA05    Nifedipine               30 mg      O, P         2       0.071
  C08DA01    Verapamil                0.24 g     O, P         50      1.134
  C08DB01    Diltiazem                0.24 g     O            3       0.062
  C09AA02    Enalapril                10 mg      O, P         792     58.436
  C09AA05    Ramipril                 2.5 mg     O            4       0.284
  C09CA07    Telmisartan              40 mg      O            12      4.676
  C10AA05    Atorvastatin             20 mg      O            903     64.601
  B01AA03    Warfarin                 7.5 mg     O, P         2       0.0411
  B01AA07    Acenocoumarol            5 mg       O            38      1.2804
  B01AB01    Heparin                  10 TU      P            67      0.0397
  B01AB05    Enoxaparin               2 TU       P            615     0.2187
  B01AC04    Clopidogrel              75 mg      O            738     53.196
  B01AC06    Acetylsalicylic acid     1 tab      O            816     58.14
  B01AD01    Streptokinase            1.5 MU     P            123     1.458
  B01AD11    Tenecteplase             40 mg      P            10      0.089
  R03AC02    Salbutamol               0.8 mg     Inhalation   155     6.18
  J01DD04    Ceftriaxone              2 g        P            255     21.33

ATC=Anatomical-therapeutic-chemical, DDD=Defined daily dose, O=Oral, P=Parenteral, RoA=Route of administration, SL=Sublingual

###### 

Overall drug utilization in total number of prescriptions of the study population

  Drugs prescribed                                     In-hospital (*n*=1120)   At discharge (*n*=877)
  ---------------------------------------------------- ------------------------ ------------------------
  Cardiac drugs                                                                 
   Antiplatelets                                       964 (86.07)              716 (81.64)
   Anticoagulants                                      623 (55.62)              24 (27.37)
   Thrombolytics                                       133 (11.87)              0
   Antianginals                                        638 (56.96)              347 (39.58)
   Statins                                             903 (80.62)              672 (76.62)
   ACE inhibitors                                      795 (70.98)              568 (64.77)
   Angiotensin receptor blocker                        12 (1.07)                11 (1.25)
   Beta blockers                                       471 (42.05)              566 (64.54)
   Alpha and beta blockers                             225 (20.09)              192 (21.89)
   Diuretics                                           738 (65.89)              483 (55.07)
   Antiarrhythmics                                     47 (4.2)                 13 (1.48)
   Calcium channel blockers                            121 (10.8)               71 (8.1)
   Inotropes                                           356 (31.79)              134 (15.28)
  Noncardiac drugs                                                              
   Oxygen                                              467 (41.7)               0
   Bronchodilators                                     226 (20.18)              47 (5.36)
   Intravenous fluids                                  381 (34.02)              0
   Antidiabetics                                       180 (16.07)              144 (16.42)
   Antibiotics                                         433 (38.66)              139 (15.85)
   Centrally acting drugs                              183 (16.34)              43 (4.9)
   Antiulcer drugs                                     938 (83.75)              616 (70.24)
   Antihistamines                                      171 (15.27)              5 (0.57)
   Laxatives                                           127 (11.34)              11 (1.25)
   Mucokinetics                                        134 (11.96)              23 (2.62)
   Antiemetics                                         110 (9.82)               12 (1.37)
   Antidiarrheals                                      38 (3.39)                4 (0.46)
   Analgesic, anti-inflammatory, and muscle relaxant   86 (7.68)                84 (9.58)
   Thyroid drugs                                       11 (0.09)                12 (1.37)
   Vitamin supplements                                 298 (26.61)              388 (44.24)
   Overall electrolyte                                 394 (35.18)              131 (14.94)
   Erectile dysfunction drugs                          48 (4.29)                37 (4.22)
   Antivertigo                                         15 (1.34)                5 (0.57)
   Ursodeoxycholic acid                                11 (0.09)                5 (0.57)
   Benign prostatic hyperplasia drug                   1 (0.01)                 1 (0.1)

ACE=Angiotensin-converting enzyme

### Antiplatelets {#sec3-1}

Aspirin was the major antiplatelet prescribed in 72.86%, followed by clopidogrel in 65.89% of prescriptions. Only 21.7% of prescriptions have fixed combination of these two medications. In ACS, only 80.67% were prescribed with aspirin and 77.45% with clopidogrel.

### Anticoagulants {#sec3-2}

Enoxaparin, low-molecular-weight heparin (LMWH) utilization, was predominated in 53.66% of prescriptions compared to 4.73% with unfractionated heparin. Based on the physician recommendations, both are sequentially prescribed in 1.25% of prescriptions. Among oral anticoagulants, acenocoumarol (acitrom) was prescribed in 3.39%, followed by warfarin in 0.18% of prescriptions. Males have received more LMWH (58.03%) and unfractionated heparin (62.26%) than females.

### Thrombolytics {#sec3-3}

Streptokinase (10.98%) was mostly prescribed whereas tenecteplase (0.89%) was found in few cases as it was newly introduced in the hospital drug formulary due to its beneficial effects and ease of administration compared to streptokinase. Only about 16.7% were prescribed with streptokinase in ACS patients.

### Lipid-lowering agents {#sec3-4}

Atorvastatin was commonly prescribed in 80.62% of prescriptions.

### Inotropic agents {#sec3-5}

Digoxin was mostly prescribed (20.09%) and others were least prescribed (atropine, 6.96%; dopamine, 5.71%; dobutamine, 5%; adrenaline, 4.82%; and noradrenaline, 4.10%). About 35.9% of HF patients were prescribed with digoxin.

### Antiarrhythmics {#sec3-6}

Amiodarone was found in 3.75% of prescriptions, followed by adenosine and isoprenaline (0.71% and 0.09%, respectively).

### Antihypertensive agents {#sec3-7}

Among ACE inhibitors, enalapril was prescribed in 70.08%, followed by ramipril in 0.27% of prescriptions. Angiotensin receptor blockers (ARBs) were prescribed least, i.e., telmisartan in 0.89% and combination drug (telmisartan + hydrochlorothiazide) in 0.18% of prescriptions. Among diuretics, majority of prescriptions have furosemide (63.84%) than torasemide (1.61%), metolazone (15.09%), spironolactone (12.14%), and diuretic combination (4.02%). The use of diuretic was about 87.56% in HF. Beta blockers such as metaprolol, atenolol, and propranolol were prescribed in 43.57%, 0.27%, and 0.09% of prescriptions, respectively. Only 42.56% in ACS and 38.34% in HF were given beta blockers. Alpha and beta blockers such as carvedilol and labetalol were prescribed in 19.91% and 0.27% of prescriptions, respectively. Among calcium channel blockers (CCBs), amlodipine (6.16%) was mainly prescribed compared to diltiazem (0.27%) and verapamil (4.46%). Centrally acting antihypertensive methyldopa was prescribed in 0.09% of prescriptions.

### Antianginal agents {#sec3-8}

Isosorbide dinitrate was mostly prescribed in 45.98% of prescriptions and other antianginals include nicorandil (14.46%), oral glyceryl trinitrate (9.82%), injectable glyceryl trinitrate (9.46%), isosorbide mononitrate (5.27%), ivabradine (0.98%), and ranolazine (0.27%). In ACS, only 11.63% were prescribed with nitrates.

### Others {#sec3-9}

Among noncardiac drugs, pantoprazole (80.44%) was prescribed mostly, followed by intravenous fluid normal saline, 31.7%; ceftriaxone, 22.77%; multivitamin, 18.75%; tramadol, 13.75%; alprazolam, 12.77%; and Phenergan, 12.77%. An overview of noncardiac drugs is provided in [Table 2](#T2){ref-type="table"}.

Prescription pattern during discharge {#sec2-7}
-------------------------------------

The average drugs per prescription during hospitalization was 11.55 (range of 2--32) and during discharge was 6.55 (range of 2--10) with least number of drugs with generic names shown in [Table 3](#T3){ref-type="table"}. During discharge, majority were prescribed with antiplatelets, 81.64%; statins, 76.62%; ACE inhibitors, 64.77%; beta blockers, 64.54%; diuretics, 55.07%; and antianginals, 39.58%, followed by anticoagulants, nonselective beta blockers, cardiotonic, CCBs, and ARBs, and the details are summarized in [Table 2](#T2){ref-type="table"}. All the prescribed drugs are present in EDL and meet the standard treatment guidelines. Females received less aspirin (42.56%), statins (39.58%), and ACE inhibitors (41.7%) than males.

###### 

Pattern of prescription writing using the World Health Organization prescribing indicators in the study population

  Prescribing Indicators (optimal level)                             In-hospital (*n*=1120), %   At discharge (*n*=877), %
  ------------------------------------------------------------------ --------------------------- ---------------------------
  Average number of drugs prescribed per prescription (≤3)           11.55                       6.55
  Percentage of drugs prescribed by generic name (100%)              26.86                       18.95
  Percentage of prescriptions with an antibiotic prescribed (≤30%)   38.66                       15.85
  Percentage of prescriptions with an injection prescribed (≤10%)    99.55                       6.27
  Percentage of drugs prescribed from the national EDL (100%)        97.01                       94.74

EDL=Essential drug list

Prescription errors {#sec2-8}
-------------------

Negligible prescription errors were found in the discharge medication, in which the type of error was repetition of drug and more drugs of the same class which may lead to increase in dose and possibly development of serious side effects.

Discussion {#sec1-4}
==========

Gender distribution was nearly equal, and majority were younger (\<45 years) similar to CREATE registry\[[@ref3]\] than those in observational studies of developed countries (63--69 years).\[[@ref15][@ref16]\] Coronary artery disease and cardiomyopathy were the common causes of hospitalization. It was reported that the rate of STEMI and NSTEMI is equal in patients with IHD unlike CREATE study.\[[@ref3]\] In contrast to DEMAT study,\[[@ref4]\] both the genders of the present study are equal in the ACS prevalence despite the occurrence of potential confounders. Compared to national data on cardiovascular mortality rate (26%),\[[@ref2]\] the present findings inhospital mortality was 8.21% within the margin where most deaths due to ACS are documented, which would be the cause for developing arrhythmias and HF.

Antiplatelets, statins, ACE inhibitors, and diuretics were mostly prescribed, which certainly improve the treatment outcomes. Almost all patients received antiplatelets similar to other centers in Southern India.\[[@ref17][@ref18]\] Enoxaparin was found effective in treating pulmonary embolism, venous thrombosis, and unstable angina,\[[@ref19]\] and the utilization of anticoagulants was optimal to other Indian studies (75%--85%).\[[@ref3][@ref20]\] Recent addition of tenecteplase in the hospital drug formulary was identified in the study which was proved more advantageous than streptokinase. The use of streptokinase was less where only about 10.98% were thrombolyzed within the window period for myocardial damage. Atorvastatin was the only lipid-lowering drug utilized, but it was found that the dose was not calculated according to low-density lipoprotein cholesterol levels and was lower than the recommended use. The use of ACE inhibitors and statins was optimal and similar to other studies.\[[@ref3][@ref18]\] Inotrope use is short term to stabilize the hemodynamic status as long-term use escalates mortality. Similar to ACS-US registry,\[[@ref21]\] females receive less heparin and ACE inhibitors, aspirin, and statins than males.

The DDD concept provides a rough estimate on the number of units of drug used per 100 beds in a day. It was assumed that every patient prescribed with a definite drug takes specific DDD \[[Table 1](#T1){ref-type="table"}\] every day, disregard to the dosage alteration and the patient-related factors. It was observed that DDD of furosemide was markedly high in comparison with others; therefore, it has to be utilized with precaution as it results in nutrient deficiencies with fluid loss.

The use of aspirin, clopidogrel, beta blockers, and ACE inhibitors in ACS was low, compared to East\[[@ref7]\] and South India\[[@ref8][@ref9]\] and high in some regions of South India.\[[@ref10]\] In HF, the use of diuretics and beta blockers was almost equal,\[[@ref11]\] whereas the use of digoxin and ACE inhibitors was high compared to South India.\[[@ref11][@ref12]\]

Polypharmacy was high for discharged patients and it may be acceptable as the study center is a tertiary care setting where majority of patients are hospitalized with several comorbidities. A relationship between polypharmacy and comorbidities is a proven risk factor for adverse reactions, which significantly augment the duration of hospitalization.\[[@ref22]\] It is strongly recommended that the use of generic name in prescriptions enable improved information exchange and better communication between health-care providers.\[[@ref23]\] A very low percentage of drugs, prescribed by generic name, was found, which is a major concern. Appropriate use of antibiotics and injectables was found in the study. As the inpatients receive more injections, probability to promote risk of blood-borne diseases is also high. However, the overuse/misuse of antibiotics is a global threat\[[@ref24]\] and the use of injectables depends on the patients\' condition, regardless of the availability of oral dosages during hospital stay. All the drugs used were from the EDL, which is imperative to promote rational drug use and cost effectiveness.\[[@ref25]\] Prescription errors can be reduced using generic names, and polytherapy could be reduced using fixed combinations rather than single formulation which may potentially improve drug utilization.

Conclusion {#sec1-5}
==========

The study concludes that during the study period, males were mostly admitted and the mortality rate was high in females. Irrational drug uses such as polypharmacy and nongeneric names were observed in the prescriptions. Cardiovascular drug doses are appropriate as the study center is a government one and here major concern relies on whether the drug was prescribed to the patient or not. Hence, rational drug use relies on accurate prescription writing, patient education, and compliance to the treatment which is vital in achieving the appropriate beneficial outcome.
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